{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T22:00:59Z","timestamp":1789077659382,"version":"build-2803163510"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017009","name":"Institute of Nano Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["5\/8\/5\/68\/Adhoc\/2020\/ECD-I"],"award-info":[{"award-number":["5\/8\/5\/68\/Adhoc\/2020\/ECD-I"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jconrel.2024.12.031","type":"journal-article","created":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T15:51:13Z","timestamp":1735228273000},"page":"671-686","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Trans-nasal brain delivery of anti-TB drugs by methyl-\u03b2-cyclodextrin microparticles show efficient mycobacterial clearance from central nervous system"],"prefix":"10.1016","volume":"378","author":[{"given":"Krishna","family":"Jadhav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agrim","family":"Jhilta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghuraj","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shweta","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swarnima","family":"Negi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailash","family":"Ahirwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul Kumar","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2024.12.031_bb0005","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrneurol.2017.120","article-title":"Tuberculous meningitis","volume":"13","author":"Wilkinson","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jconrel.2024.12.031_bb0010","article-title":"Challenges in the diagnosis of tuberculous meningitis","volume":"20","author":"Palacios","year":"2020","journal-title":"J. Clin. Tuberculos. Other Mycobact. Dis."},{"key":"10.1016\/j.jconrel.2024.12.031_bb0015","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1164\/ajrccm\/148.3.650","article-title":"Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis","volume":"148","author":"Ellard","year":"1993","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.jconrel.2024.12.031_bb0020","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.3390\/ijms23126436","article-title":"Mycobacterium tuberculosis infection induces Bcsfb disruption but no Bbb disruption in vivo: implications in the pathophysiology of tuberculous meningitis","volume":"23","author":"S\u00e1nchez-Garibay","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2024.12.031_bb0025","article-title":"Population pharmacokinetic analysis of rifampicin in plasma, cerebrospinal fluid, and brain extracellular fluid in South African children with tuberculous meningitis","volume":"67","author":"Abdelgawad","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2024.12.031_bb0030","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.tube.2010.07.002","article-title":"Cerebrospinal fluid concentrations of antituberculosis agents in adults and children","volume":"90","author":"Donald","year":"2010","journal-title":"Tuberculosis"},{"key":"10.1016\/j.jconrel.2024.12.031_bb0035","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/17512433.2019.1552831","article-title":"Intensified antibiotic treatment of tuberculosis meningitis","volume":"12","author":"Cresswell","year":"2019","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.jconrel.2024.12.031_bb0040","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1124\/jpet.119.258152","article-title":"Nose-to-brain delivery","volume":"370","author":"Wang","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jconrel.2024.12.031_bb0045","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijpharm.2018.10.029","article-title":"Advanced formulations for intranasal delivery of biologics","volume":"553","author":"Rohrer","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2024.12.031_bb0050","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13346-020-00891-5","article-title":"Intranasal drug delivery: opportunities and toxicologic challenges during drug development","volume":"12","author":"Keller","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2024.12.031_bb0055","first-page":"83","article-title":"Enhanced brain uptake of rifampicin from W\/O\/W multiple emulsions via nasal route","volume":"58","author":"Khopade","year":"1996","journal-title":"Indian J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2024.12.031_bb0060","doi-asserted-by":"crossref","first-page":"189","DOI":"10.5530\/ijper.54.2s.75","article-title":"Lipid-based nano formulation approach to target brain for the management of tuberculosis through intranasal delivery: formulation development and evaluation","volume":"54","author":"Upadhyayula","year":"2020","journal-title":"Indian J. Pharm. Educ. Res."},{"key":"10.1016\/j.jconrel.2024.12.031_bb0065","doi-asserted-by":"crossref","DOI":"10.1039\/D4NR02621G","article-title":"Effective cerebral tuberculosis treatment via nose-to-brain transport of anti-Tb drugs using muco-adhesive nano-aggregates","author":"Jadhav","year":"2024","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2024.12.031_bb0070","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jconrel.2023.01.070","article-title":"Nasal administration of a temozolomide-loaded thermoresponsive nanoemulsion reduces tumor growth in a preclinical glioblastoma model","volume":"355","author":"Michels","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.12.031_bb0075","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2174\/1389203723666220526161109","article-title":"Taming the devil: antimicrobial peptides for safer Tb therapeutics","volume":"23","author":"Jadhav","year":"2022","journal-title":"Curr. Protein Pept. Sci."},{"key":"10.1016\/j.jconrel.2024.12.031_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2023.104261","article-title":"Nanotherapeutics for pulmonary drug delivery: an emerging approach to overcome respiratory diseases","author":"Kole","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.jconrel.2024.12.031_bb0085","doi-asserted-by":"crossref","DOI":"10.1021\/acsinfecdis.4c00385","article-title":"Breaking the cycle: matrix metalloproteinase inhibitors as an alternative approach in managing tuberculosis pathogenesis and progression","author":"Jhilta","year":"2024","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.jconrel.2024.12.031_bb0090","series-title":"Nanostructured Drug Delivery Systems in Infectious Disease Treatment","first-page":"123","article-title":"Chapter 6 - Therapeutic potential of nano assisted delivery in tuberculosis and its management","author":"Singh","year":"2024"},{"key":"10.1016\/j.jconrel.2024.12.031_bb0095","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/bcpt.12917","article-title":"Cyclodextrin-based formulations: a non-invasive platform for targeted drug delivery","volume":"122","author":"Muankaew","year":"2018","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.jconrel.2024.12.031_bb0100","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.carbpol.2013.08.027","article-title":"Chitosan and cyclodextrin in intranasal microemulsion for improved brain buspirone hydrochloride pharmacokinetics in rats","volume":"99","author":"Bshara","year":"2014","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.jconrel.2024.12.031_bb0105","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0169-409X(98)00054-4","article-title":"Cyclodextrins in nasal drug delivery","volume":"36","author":"Merkus","year":"1999","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.12.031_bb0110","doi-asserted-by":"crossref","first-page":"E329","DOI":"10.1208\/pt060243","article-title":"Cyclodextrins in drug delivery: an updated review","volume":"6","author":"Challa","year":"2005","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2024.12.031_bb0115","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jconrel.2021.05.020","article-title":"Nasal biocompatible powder of geraniol oil complexed with cyclodextrins for neurodegenerative diseases: physicochemical characterization and in vivo evidences of nose to brain delivery","volume":"335","author":"Truzzi","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.12.031_bb0120","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0168-3659(98)00115-1","article-title":"The effect of methylated \u0392-cyclodextrins on the tight junctions of the rat nasal respiratory epithelium:: electron microscopic and confocal laser scanning microscopic visualization studies","volume":"57","author":"Marttin","year":"1999","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.12.031_bb0125","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jconrel.2015.01.025","article-title":"Solid microparticles based on chitosan or methyl-\u0392-cyclodextrin: a first formulative approach to increase the nose-to-brain transport of deferoxamine mesylate","volume":"201","author":"Rassu","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.12.031_bb0130","doi-asserted-by":"crossref","first-page":"14700","DOI":"10.1007\/s10853-021-06205-5","article-title":"Systematic development and optimization of spray-dried quercetin-Hp-\u0392-cyclodextrin microparticles for dpi-based therapy of lung cancer","volume":"56","author":"Vaghasiya","year":"2021","journal-title":"J. Mater. Sci."},{"key":"10.1016\/j.jconrel.2024.12.031_bb0135","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1080\/02652048.2016.1260659","article-title":"Resveratrol solid lipid microparticles as dry powder formulation for nasal delivery, characterization and in vitro deposition study","volume":"33","author":"Martignoni","year":"2016","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.jconrel.2024.12.031_bb0140","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1080\/03639045.2017.1321659","article-title":"Development of a soluplus budesonide freeze-dried powder for nasal drug delivery","volume":"43","author":"Pozzoli","year":"2017","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2024.12.031_bb0145","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jconrel.2023.04.029","article-title":"Neutralisation of Sars-Cov-2 by monoclonal antibody through dual targeting powder formulation","volume":"358","author":"Seow","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.12.031_bb0150","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1080\/1061186X.2019.1574300","article-title":"Anti-inflammatory flurbiprofen nasal powders for nose-to-brain delivery in Alzheimer\u2019s disease","volume":"27","author":"Tiozzo Fasiolo","year":"2019","journal-title":"J. Drug Target."},{"key":"10.1016\/j.jconrel.2024.12.031_bb0155","doi-asserted-by":"crossref","first-page":"21360","DOI":"10.1021\/acsami.9b04766","article-title":"Mixed mucoadhesive amphiphilic polymeric nanoparticles cross a model of nasal septum epithelium in vitro","volume":"11","author":"Schlachet","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2024.12.031_bb0160","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejpb.2019.10.008","article-title":"Suitability of Rpmi 2650 cell models for nasal drug permeability prediction","volume":"145","author":"Sibinovska","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2024.12.031_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2021.112027","article-title":"Efficient, enzyme responsive and tumor receptor targeting gelatin nanoparticles decorated with concanavalin-a for site-specific and controlled drug delivery for cancer therapy","volume":"123","author":"Vaghasiya","year":"2021","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.jconrel.2024.12.031_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122585","article-title":"Fat fighting liraglutide based nano-formulation to reverse obesity: design, development and animal trials","volume":"634","author":"Jakhar","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2024.12.031_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2024.213853","article-title":"Self-actuating inflammation responsive hydrogel microsphere formulation for controlled drug release in rheumatoid arthritis (Ra): animal trials and study in human fibroblast like synoviocytes (Hfls) of Ra patients","volume":"160","author":"Singh","year":"2024","journal-title":"Biomater. Adv."},{"key":"10.1016\/j.jconrel.2024.12.031_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121097","article-title":"Antimicrobial activity of synthetic antimicrobial peptides loaded in poly-\u0190-caprolactone nanoparticles against mycobacteria and their functional synergy with rifampicin","volume":"608","author":"Sharma","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2024.12.031_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2023.213594","article-title":"Clofazimine nanoclusters show high efficacy in experimental Tb with amelioration in paradoxical lung inflammation","volume":"154","author":"Jadhav","year":"2023","journal-title":"Biomater. Adv."},{"key":"10.1016\/j.jconrel.2024.12.031_bb0190","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1128\/AAC.00153-08","article-title":"Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice","volume":"52","author":"Verma Rahul","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2024.12.031_bb0195","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jconrel.2018.10.020","article-title":"Intranasal immunization with aluminum salt-adjuvanted dry powder vaccine","volume":"292","author":"Thakkar","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2024.12.031_bb0200","doi-asserted-by":"crossref","first-page":"852","DOI":"10.3390\/pharmaceutics13060852","article-title":"Spray freeze dried Lyospheres\u00ae for nasal administration of insulin","volume":"13","author":"Serim","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2024.12.031_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121658","article-title":"Particulate levodopa nose-to-brain delivery targets dopamine to the brain with no plasma exposure","volume":"618","author":"Dimiou","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2024.12.031_bb0210","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3390\/pharmaceutics14020369","article-title":"Applicability of Rpmi 2650 and Calu-3 cell models for evaluation of nasal formulations","volume":"14","author":"Sibinovska","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2024.12.031_bb0215","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2147\/IJN.S397650","article-title":"In vitro evaluation of paliperidone palmitate loaded cubosomes effective for nasal-to-brain delivery","author":"Deruyver","year":"2023","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2024.12.031_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122630","article-title":"Optimising nasal powder drug delivery\u2013characterisation of the effect of excipients on drug absorption","volume":"633","author":"Trenkel","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2024.12.031_bb0225","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s12936-022-04309-0","article-title":"Pre-referral intranasal Artesunate powder for cerebral malaria: a proof-of-concept study","volume":"21","author":"Kouakou","year":"2022","journal-title":"Malar. J."},{"key":"10.1016\/j.jconrel.2024.12.031_bb0230","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.3390\/pharmaceutics13081180","article-title":"Versatile nasal application of cyclodextrins: excipients and\/or actives?","volume":"13","author":"Rassu","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2024.12.031_bb0235","doi-asserted-by":"crossref","first-page":"59","DOI":"10.21315\/mjms2018.25.6.6","article-title":"Direct resazurin microplate assay in drug susceptibility testing of smear-positive sputum samples against mycobacterium tuberculosis","volume":"25","author":"Jamil","year":"2018","journal-title":"Malays. J. Med. Sci. MJMS"},{"key":"10.1016\/j.jconrel.2024.12.031_bb0240","doi-asserted-by":"crossref","first-page":"833","DOI":"10.4103\/ijmr.IJMR_1930_15","article-title":"Modelling of cerebral tuberculosis in Balb\/C mice using clinical strain from patients with Cns tuberculosis infection","volume":"145","author":"Husain","year":"2017","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.jconrel.2024.12.031_bb0245","doi-asserted-by":"crossref","DOI":"10.1172\/JCI155851","article-title":"High-dose rifampin improves bactericidal activity without increased intracerebral inflammation in animal models of tuberculous meningitis","volume":"132","author":"Ruiz-Bedoya","year":"2022","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2024.12.031_bb0250","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.4049\/jimmunol.181.3.2076","article-title":"Il-10 helps control pathogen load during high-level bacteremia1","volume":"181","author":"Londo\u00f1o","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2024.12.031_bb0255","first-page":"1","article-title":"A critical review on developments in drying technologies for enhanced stability and bioavailability of pharmaceuticals","author":"Jadhav","year":"2024","journal-title":"Dry. Technol."},{"key":"10.1016\/j.jconrel.2024.12.031_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(22)00359-7","article-title":"Who\u2019s global tuberculosis report 2022","volume":"4","author":"Bagcchi","year":"2023","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.jconrel.2024.12.031_bb0265","doi-asserted-by":"crossref","first-page":"10957","DOI":"10.1038\/s41598-017-11438-z","article-title":"Sex differences in the C57bl\/6 model of mycobacterium tuberculosis infection","volume":"7","author":"Dibbern","year":"2017","journal-title":"Sci. Rep."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924008836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924008836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T12:45:21Z","timestamp":1778244321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924008836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":53,"alternative-id":["S0168365924008836"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.12.031","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trans-nasal brain delivery of anti-TB drugs by methyl-\u03b2-cyclodextrin microparticles show efficient mycobacterial clearance from central nervous system","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.12.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}